| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.098 | 0.007 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.009 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.084 | 0.009 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.009 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.17 | 0.01 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.01 |